bluebird bio, Inc. (BLUE) is down 40.17 percent during Friday's trading, falling $2.83 to trade at $4.21 after announcing a definitive agreement to be acquired by Carlyle and SK Capital Partners.
The stock opened at $4.91 and has traded between $4.00 and $5.65 today. Volume has surged to 4.27 million shares, well above its average of 392,053. BLUE's 52-week range is $4.00 to $38.40.
The deal includes a leadership transition, with David Meek expected to become CEO upon closing.
For comments and feedback: editorial@rttnews.com